| Detection and Its Clinical Significance of EGFR Gene Mutation and Gene Amplification in 187 Patients with Non-small Cell Lung Cancer |
PDF
HTML
|
|
Hongyu LIU, Ying LI, Gang CHEN, Jing WANG, Yongwen LI, Yuli WANG, Sen WEI, Daxing ZHU, Xiaoming QIU, Weiqiang WANG, Zuoqing SONG, Jun CHEN, Qinghua ZHOU |
1219-1228 |
| The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis |
PDF
HTML
|
|
Zhijie WANG, Lu YANG, Tongtong AN, Jun ZHAO, Hua BAI, Jianchun DUAN, Meina WU, Minglei ZHUO, Yuyan WANG, Jie WANG |
1247-1254 |
| A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer |
PDF
HTML
|
|
Huiling GUO, Rongfang ZHANG, Qimei YANG, Lingjuan ZHANG, Kehu YANG, Jinhui TIAN |
1260-1265 |
| Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer |
PDF
HTML
|
|
Junfang TANG, Yunzhong ZHU, Zhe LIU, Wei WU, Zan LIU, Heling SHI, Qiyi MENG, Mingzhi LI, Yuhua WU, Liyan XU |
1276-1281 |
| A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer |
PDF
HTML
|
|
Yuhua WU, Hong TAO, Junfang TANG, Xinyong ZHANG, Yunzhong ZHU, Zhe LIU, Heling SHI, Qiyi MENG, Wei WU, Zan LIU, Lili GUO, Mingzhi LI, Liyan XU |
1309-1311 |
| Role of miRNAs in Lung Cancer |
PDF
HTML
|
|
William C.S. Cho |
1312-1315 |
| Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non–small Cell Lung Cancer Therapy |
PDF
HTML
|
|
Juan NAN, Qian LIU, Yan DING, Zhanque ZHANG, Allen C. Gao, Qinghua ZHOU |
1316-1324 |
| The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance |
PDF
HTML
|
|
Jun PEI, Baohui HAN |
1325-1329 |
| Erlotinib-induced Skin Rash in Patients with Non–small Cell Lung Cancer: Pathogenesis, Clinical Significance and Treatment |
PDF
HTML
|
|
Yan DING, Qian LIU, Juan NAN, Qinghua ZHOU |
1330-1336 |
| Erlotinib in Patients with Brain Metastases for Non-small Cell Lung Cancer |
PDF
HTML
|
|
Jiandong ZHANG, Xinshuang YU, Jinming YU |
1337-1340 |
| Advanced Research on the Response of EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer Therapy |
PDF
HTML
|
|
Xifeng DONG, Qiang SONG |
1341-1345 |
| Mechanisms of Acquired Resisitance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer |
PDF
HTML
|
|
Xiaoping LI, Hongjie LI |
1346-1351 |
| Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancerr |
PDF
HTML
|
|
Fanlu MENG, Li MA |
1352-1355 |
| Biomarkers of Patients with Non-small Cell Lung Cancer who Benefited from Erlotinib Treatment |
PDF
HTML
|
|
Dali HAN, Jinmimg YU |
1356-1358 |
| Advances of Targeted therapies in Non-small Cell Lung Cancer |
PDF
HTML
|
|
Ruixiu ZHANG, Yong ZHAO, Zhanque ZHANG |
1359-1364 |
| Molecular Predictor to Response and Toxicity of EGFR-targeted Medicines in Lung Cancer |
PDF
HTML
|
|
Cunwei CAI |
1365-1368 |
| Advances of KRAS Mutation in Non-small Cell Lung Cancer |
PDF
HTML
|
|
Yang LI |
1369-1373 |
| A Case Report of Erlotinib as First-line Therapy in Extensive Metastatic Patient with Advanced Non-small Cell Lung Cancera |
PDF
HTML
|
|
Wanfeng GUO, Xiaoqing LIU |
1374-1376 |